Literature DB >> 25956724

The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients.

Shin Hwang1, Young-Joo Lee, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Sung-Gyu Lee.   

Abstract

BACKGROUND: According to the 7th AJCC TNM staging system, solitary hepatocellular carcinoma (HCC) is classified as T1 or T2 based on microvascular invasion (MVI) regardless of tumor size. This study intended to evaluate the prognostic impact of tumor size on survival outcomes after macroscopic curative resection of solitary HCC.
METHODS: Patients who underwent R0 resection of solitary HCC <10 cm (n = 2558) were selected for study. Follow-up lasted ≥24 months or until death.
RESULTS: HCC was detected during regular health screening or routine follow-up in 2054 cases (80.3%). Hepatitis B virus (HBV) infection was associated in 2127 (83.2%). Mean patient age was 54.4 ± 9.9 years. Anatomical resection was performed in 1786 (69.8%). MVI was identified in 407 (16.0%) which therefore became stage T2; the other 2150 became stage T1. Tumor recurrence and patient survival rates were 24.9 and 95.0% after 1 year, 49.6 and 84.1% after 3 years, 57.7 and 75.0 % after 5 years, and 67.3 and 56.6% after 10 years, respectively. Multivariate analysis showed that non-anatomical resection, MVI, and tumor size >5 cm were independent risk factors for both tumor recurrence and overall patient survival. Long-term survival correlated negatively with tumor size and MVI. Subgroup analysis with MVI and size cutoff of 5 cm revealed a significant survival difference (p = 0.000). Tumor size >5 cm was not a significant prognostic factor in non-HBV patients.
CONCLUSIONS: These results suggest that the prognostic impact of tumor size may be underestimated in the current version of the AJCC staging system and that solitary HCC staging could be improved with inclusion of tumor size cutoff of 5 cm in HBV-associated patients. Further validation is necessary with multicenter studies.

Entities:  

Mesh:

Year:  2015        PMID: 25956724     DOI: 10.1007/s11605-015-2849-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

1.  Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes.

Authors:  Alastair L Young; Robert Adair; K Rajendra Prasad; Giles J Toogood; J Peter A Lodge
Journal:  J Am Coll Surg       Date:  2011-12-03       Impact factor: 6.113

Review 2.  Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis.

Authors:  Yanming Zhou; Zhansai Zhang; Yanfang Zhao; Lupeng Wu; Bin Li
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

3.  Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion.

Authors:  Han Zhang; Shou-Xin Yuan; Shu-Yang Dai; Jin-Min Zhang; Xing Huang; Chong-De Lu; Jun-Hua Lu; Fu-Quan Wu; Wan Yee Lau; Meng-Chao Wu; Tian Yang; Feng Shen
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

4.  The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas.

Authors:  Sung Gwe Ahn; Sung Hoon Kim; Tae Joo Jeon; Ho Jin Cho; Sae Byeol Choi; Mi Jin Yun; Jong Doo Lee; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2011-09-09       Impact factor: 3.452

5.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection.

Authors:  Lian-Yue Yang; Feng Fang; Di-Peng Ou; Wei Wu; Zhi-Jun Zeng; Fan Wu
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

9.  Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors.

Authors:  Junichi Shindoh; Andreas Andreou; Thomas A Aloia; Giuseppe Zimmitti; Gregory Y Lauwers; Alexis Laurent; David M Nagorney; Jacques Belghiti; Daniel Cherqui; Ronnie Tung-Ping Poon; Norihiro Kokudo; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2012-11-21       Impact factor: 5.344

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  58 in total

1.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

2.  Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study.

Authors:  Wenjie Zhang; Kangpeng Jin; Fei Wang; Guangyan Zhangyuan; Weiwei Yu; Yang Liu; Haitian Zhang; Ping Zhang; Beicheng Sun
Journal:  United European Gastroenterol J       Date:  2019-04-24       Impact factor: 4.623

3.  Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification.

Authors:  Dong-Hwan Jung; Shin Hwang; Seung-Mo Hong; Yong-Kyu Chung; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gil-Chun Park; Han Chu Lee; Young-Suk Lim; Eun Sil Yu; Sung-Gyu Lee
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

4.  Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma.

Authors:  Chao Zhou; Yuejun Sun; Shuwei Guo; Xiao Chen; Genchong Bao; Jiandong Wang
Journal:  Dig Dis Sci       Date:  2017-11-10       Impact factor: 3.199

5.  Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study.

Authors:  Qing-Wang Ye; Shu-Jie Pang; Ning Yang; Hai-Bin Zhang; Yong Fu; Bin Lin; Guang-Shun Yang
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

6.  Comparison of the efficacy of pre-surgery and post-surgery radiotherapy in the treatment of hepatocellular carcinoma: a population-based study.

Authors:  Lei Chen; Xiaopeng Guo; Shi Chen; Yanqiao Ren; Tao Sun; Fan Yang; Chuansheng Zheng
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

7.  Treatment and outcomes of recurrent hepatocellular carcinomas.

Authors:  Gaëtan-Romain Joliat; Pierre Allemann; Ismail Labgaa; Nicolas Demartines; Nermin Halkic
Journal:  Langenbecks Arch Surg       Date:  2017-05-11       Impact factor: 3.445

8.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Young-In Yoon; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jong-Woo Lee; Seung-Mo Hong; Eun Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-12-01       Impact factor: 3.452

9.  Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Dong-Hwan Jung; Shin Hwang; Ki-Hun Kim; Seung-Mo Hong; Young-Joo Lee; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Gil-Chun Park; Eun Sil Yu; Sung-Gyu Lee
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

10.  Hypermethylation of NF-κB-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis.

Authors:  Patrick Kwok Shing Ng; Carol Po Ying Lau; Emily Kai Yee Lam; Sheila Sai Kam Li; Vivian Wai Yan Lui; Winnie Yeo; Yuen Keng Ng; Paul Bo San Lai; Stephen Kwok Wing Tsui
Journal:  Dig Dis Sci       Date:  2018-01-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.